GlassScriptPhysician profile
Nisha Kuruvadi
NPI 1104322239
$2,805.43
in general payments reported to CMS, 2019-2025
25 companies · $777 in 2025
The $777 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.52 · 2021: $95.00 · 2022: $539 · 2023: $388 · 2024: $987 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,086.01 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $383.47 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $381.84 | 2021-2025 | |
| Novo Nordisk INC | $316.71 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $271.61 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.71 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $188.30 | 2024 | Veozah |
| Abbvie INC. | $182.42 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $132.98 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $132.54 | 2022-2025 | Airsupra |
| Amgen INC. | $82.12 | 2022-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $71.77 | 2022-2023 | Steglujan, Belsomra, Steglatro |
| Scilex Pharmaceuticals INC. | $66.89 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $65.06 | 2024-2025 | Austedo Xr, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.31 | 2025 | Xifaxan |
| Pfizer INC. | $53.10 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $31.50 | 2024 | Ingrezza |
| Actelion Pharmaceuticals US, INC. | $30.07 | 2024 | Opsumit, Uptravi |
| Kowa Pharmaceuticals America, INC. | $27.77 | 2021-2022 | |
| Abbott Laboratories | $22.88 | 2025 | Mitraclip |
| Mannkind Corporation | $20.64 | 2025 | |
| Jazz Pharmaceuticals INC. | $19.52 | 2020 | |
| Dynavax Technologies Corporation | $19.41 | 2023 | Heplisav-B |
| Ultragenyx Pharmaceutical INC. | $19.29 | 2022 | |
| Esperion Therapeutics, INC. | $18.66 | 2024 | Nexletol |
| Baxter Healthcare | $17.86 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Kuruvadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.